FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Granneman

Research Profile

Procedures

Physiology

Drug Interactions

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Ronald C Reed; Sandeep Dutta; John H Cavanaugh; Charles S Locke; G Richard Granneman
Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Sandeep Dutta; Yihong Qiu; Emil Samara; Guoliang Cao; G Richard Granneman
Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
Vicky Blakesley; Walid Awni; Charles S Locke; Thomas Ludden; G Richard Granneman; Lewis E Braverman
Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Granneman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Ronald C Reed; Sandeep Dutta; John H Cavanaugh; Charles S Locke; G Richard Granneman
Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Epilepsy & behavior : E&B 2006;8(2):391-6.
2005: Sandeep Dutta; Yihong Qiu; Emil Samara; Guoliang Cao; G Richard Granneman
Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
Journal of pharmaceutical sciences 2005;94(9):1949-56.
2004: Vicky Blakesley; Walid Awni; Charles S Locke; Thomas Ludden; G Richard Granneman; Lewis E Braverman
Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?
Thyroid : official journal of the American Thyroid Association 2004;14(3):191-200.
2003: Sandeep Dutta; James C Cloyd; G Richard Granneman; Stephen D Collins
Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation.
Epilepsy research 2003;53(1-2):29-38.
2003: James C Cloyd; Sandeep Dutta; Guoliang Cao; Julia K Walch; Stephen D Collins; G Richard Granneman
Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy.
Epilepsy research 2003;53(1-2):19-27.
2003: Ann Hsu; Jeffrey D Isaacson; Scott C Brun; Barry Bernstein; Wayne Lam; Richard Bertz; Cheryl Foit; Karen Rynkiewicz; Bruce Richards; Martin King; Richard Rode; Dale J Kempf; G Richard Granneman; Eugene Sun
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 2003;47(1):350-9.
2002: Sandeep Dutta; Yiming Zhang; Daniel J Daszkowski; G Richard Granneman; Marleen Verlinden
Single- and multiple-dose pharmacokinetics of fiduxosin under nonfasting conditions in healthy male subjects.
Journal of clinical pharmacology 2002;42(5):540-6.
2002: Sandeep Dutta; Yiming Zhang; Daniel J Daszkowski; G Richard Granneman; Marleen Verlinden
Multiple dose pharmacokinetics of fiduxosin under fasting conditions in healthy elderly male subjects.
The Journal of pharmacy and pharmacology 2002;54(5):641-7.
2002: Sandeep Dutta; Yiming Zhang; G Richard Granneman; Marleen Verlinden
Effect of food on the pharmacokinetics of fiduxosin in healthy male subjects.
European journal of drug metabolism and pharmacokinetics 2002;27(1):49-52.
2001: Emil Samara; Sandeep Dutta; Guoliang Cao; G Richard Granneman; M S Dordal; Robert J Padley
Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist.
Journal of clinical pharmacology 2001;41(4):397-403.
1999: Gondi N Kumar; J Dykstra; Ellen M Roberts; Venkata K Jayanti; Dean Hickman; John T Uchic; Y Yao; Bruce W Surber; Samuel Thomas; G Richard Granneman
Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(8):902-8.
1998: S L Wong; G Richard Granneman
Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies.
Journal of pharmaceutical sciences 1998;87(12):1629-31.
1998: Hing L Sham; Dale J Kempf; Akhteruzzaman Molla; Kennan Marsh; Gondi N Kumar; Chih-Ming Chen; Warren M Kati; K Stewart; R Lal; Ann Hsu; David A Betebenner; M Korneyeva; Sudthida Vasavanonda; Edith McDonald; Ayda Saldivar; Norman E Wideburg; Xiaoqi Chen; P Niu; Chang Park; Venkata K Jayanti; Brian A Grabowski; G Richard Granneman; Eugene Sun; Anthony J Japour; JM Leonard; Jacob J Plattner; Daniel W Norbeck
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
Antimicrobial agents and chemotherapy 1998;42(12):3218-24.
1998: D Ouellet; Ann Hsu; J Qian; J E Lamm; John H Cavanaugh; JM Leonard; G Richard Granneman
Effect of fluoxetine on pharmacokinetics of ritonavir.
Antimicrobial agents and chemotherapy 1998;42(12):3107-12.
1998: Ann Hsu; G Richard Granneman; Guoliang Cao; L Carothers; Anthony J Japour; Tawakol A El-Shourbagy; S Dennis; J Berg; Keith Erdman; JM Leonard; Eugene Sun
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.
Antimicrobial agents and chemotherapy 1998;42(11):2784-91.
1998: Ann Hsu; G Richard Granneman; Richard Bertz
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
Clinical pharmacokinetics 1998;35(4):275-91.
1998: D Ouellet; Ann Hsu; G Richard Granneman; G Carlson; J Cavanaugh; HJ Guenther; JM Leonard
Pharmacokinetic interaction between ritonavir and clarithromycin.
Clinical pharmacology and therapeutics 1998;64(4):355-62.
1998: D Ouellet; Ann Hsu; J Qian; Charles S Locke; C J Eason; John H Cavanaugh; JM Leonard; G Richard Granneman
Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.
British journal of clinical pharmacology 1998;46(2):111-6.
1998: Emil Samara; Linda E Gustavson; Tawakol A El-Shourbagy; Charles S Locke; G Richard Granneman; Kenneth W Sommerville
Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy.
Epilepsia 1998;39(8):868-73.
1998: Akhteruzzaman Molla; G Richard Granneman; Eugene Sun; Dale J Kempf
Recent developments in HIV protease inhibitor therapy.
Antiviral research 1998;39(1):1-23.
1998: Ann Hsu; G Richard Granneman; Guoliang Cao; L Carothers; Tawakol A El-Shourbagy; PA Baroldi; Keith Erdman; F Brown; Eugene Sun; JM Leonard
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
Clinical pharmacology and therapeutics 1998;63(4):453-64.
1998: Linda E Gustavson; Kenneth W Sommerville; SW Boellner; GF Witt; HJ Guenther; G Richard Granneman
Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate.
American journal of therapeutics 1998;5(2):73-9.
1998: SL Wong; Guoliang Cao; RJ Mack; G Richard Granneman
Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers.
International journal of clinical pharmacology and therapeutics 1998;36(3):146-51.
1998: SL Wong; Charles S Locke; J Staser; G Richard Granneman
Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers.
Psychopharmacology 1998;135(3):236-41.
1997: SL Wong; Guoliang Cao; RJ Mack; G Richard Granneman
The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers.
Journal of clinical pharmacology 1997;37(11):1056-61.
1997: Emil Samara; Guoliang Cao; Charles S Locke; G Richard Granneman; R Dean; A Killian
Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma.
Clinical pharmacology and therapeutics 1997;62(4):426-35.
1997: SL Wong; Guoliang Cao; RJ Mack; G Richard Granneman
Pharmacokinetics of sertindole in healthy young and elderly male and female subjects.
Clinical pharmacology and therapeutics 1997;62(2):157-64.
1997: SL Wong; P Linnen; RJ Mack; G Richard Granneman
Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers.
Biopharmaceutics & drug disposition 1997;18(6):533-41.
1997: Ann Hsu; G Richard Granneman; GF Witt; Charles S Locke; Jon F Denissen; Akhteruzzaman Molla; J Valdes; J Smith; Keith Erdman; N Lyons; P Niu; JP Decourt; JB Fourtillan; J Girault; JM Leonard
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.
Antimicrobial agents and chemotherapy 1997;41(5):898-905.
1997: Linda E Gustavson; SW Boellner; G Richard Granneman; JX Qian; HJ Guenther; Tawakol A El-Shourbagy; Kenneth W Sommerville
A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures.
Neurology 1997;48(4):1032-7.
1997: Richard Bertz; G Richard Granneman
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.
Clinical pharmacokinetics 1997;32(3):210-58.
1997: Dale J Kempf; Kennan Marsh; G Kumar; A David Rodrigues; Jon F Denissen; Edith McDonald; M J Kukulka; Ann Hsu; G Richard Granneman; PA Baroldi; Eugene Sun; DJ Pizzuti; Jacob J Plattner; Daniel W Norbeck; JM Leonard
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
Antimicrobial agents and chemotherapy 1997;41(3):654-60.
1997: Carol A Tamminga; RJ Mack; G Richard Granneman; C J Silber; K B Kashkin
Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety.
International clinical psychopharmacology 1997;12 Suppl 1():S29-35.
1997: SL Wong; SD Menacherry; D Mulford; P J Schmitz; Charles S Locke; G Richard Granneman
Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function.
European journal of clinical pharmacology 1997;52(3):223-7.
1996: Emil Samara; B Hosmane; Charles S Locke; C Eason; J Cavanaugh; G Richard Granneman
Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride.
Journal of clinical pharmacology 1996;36(12):1169-78.
1996: SL Wong; J Cavanaugh; H Shi; Walid Awni; G Richard Granneman
Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics.
Clinical pharmacology and therapeutics 1996;60(1):48-53.
1996: Akhteruzzaman Molla; M Korneyeva; Q Gao; Sudthida Vasavanonda; P J Schipper; H M Mo; Martin Markowitz; T Chernyavskiy; P Niu; N Lyons; Ann Hsu; G Richard Granneman; David D Ho; Charles A B Boucher; J M Leonard; Daniel W Norbeck; Dale J Kempf
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.
Nature medicine 1996;2(7):760-6.
1996: G Richard Granneman; D W Schneck; John H Cavanaugh; GF Witt
Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium.
The Journal of clinical psychiatry 1996;57(5):204-6.
1995: G Richard Granneman; Michael D Karol; Charles S Locke; John H Cavanaugh
Pharmacokinetic interaction between lansoprazole and theophylline.
Therapeutic drug monitoring 1995;17(5):460-4.
1995: Michael D Karol; G Richard Granneman; K Alexander
Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;668(1):182-6.
1995: J V St Peter; R A Braeckman; G Richard Granneman; Charles S Locke; John H Cavanaugh; Walid Awni
The effect of zileuton on antipyrine and indocyanine green disposition.
Clinical pharmacology and therapeutics 1995;57(3):299-308.
1995: Walid Awni; R A Braeckman; Charles S Locke; LM Dubé; G Richard Granneman
The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
Clinical pharmacokinetics 1995;29 Suppl 2():98-104.
1995: Walid Awni; Z Hussein; John H Cavanaugh; G Richard Granneman; LM Dubé
Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.
Clinical pharmacokinetics 1995;29 Suppl 2():92-7.
1995: Emil Samara; John H Cavanaugh; D Mukherjee; G Richard Granneman
Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
Clinical pharmacokinetics 1995;29 Suppl 2():84-91.
1995: G Richard Granneman; R A Braeckman; Charles S Locke; John H Cavanaugh; LM Dubé; Walid Awni
Effect of zileuton on theophylline pharmacokinetics.
Clinical pharmacokinetics 1995;29 Suppl 2():77-83.
1995: Walid Awni; Z Hussein; G Richard Granneman; K J Patterson; LM Dubé; John H Cavanaugh
Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.
Clinical pharmacokinetics 1995;29 Suppl 2():67-76.
1995: Walid Awni; John H Cavanaugh; GF Witt; G Richard Granneman; LM Dubé
The effect of food on the pharmacokinetics of zileuton.
Clinical pharmacokinetics 1995;29 Suppl 2():62-6.
1995: Walid Awni; John H Cavanaugh; R A Braeckman; S Y Chu; K J Patterson; J M Machinist; G Richard Granneman
The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.
Clinical pharmacokinetics 1995;29 Suppl 2():49-61.
1995: R A Braeckman; G Richard Granneman; Charles S Locke; J M Machinist; J H Cavannaugh; Walid Awni
The pharmacokinetics of zileuton in healthy young and elderly volunteers.
Clinical pharmacokinetics 1995;29 Suppl 2():42-8.
1995: Walid Awni; R A Braeckman; G Richard Granneman; GF Witt; LM Dubé
Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers.
Clinical pharmacokinetics 1995;29 Suppl 2():22-33.
1995: Walid Awni; R A Braeckman; John H Cavanaugh; Charles S Locke; P J Linnen; G Richard Granneman; LM Dubé
The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
Clinical pharmacokinetics 1995;29 Suppl 2():112-24.
1995: Walid Awni; John H Cavanaugh; T B Tzeng; GF Witt; G Richard Granneman; LM Dubé
Pharmacokinetic interactions between zileuton and prednisone.
Clinical pharmacokinetics 1995;29 Suppl 2():105-11.
1995: G Richard Granneman; R A Braeckman; Keith Erdman
Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography.
Clinical pharmacokinetics 1995;29 Suppl 2():1-8.
1995: Walid Awni; G Richard Granneman; Charles S Locke; S R Brandwein; LM Dube
Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.
European journal of clinical pharmacology 1995;48(2):155-60.
1994: Z Hussein; D Mukherjee; J Lamm; John H Cavanaugh; G Richard Granneman
Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation.
Journal of clinical pharmacology 1994;34(7):754-9.
1994: Z Hussein; Emil Samara; Charles S Locke; M A Orchard; G L Ringham; G Richard Granneman
Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2-receptor antagonist AA-2414 in normal subjects: population analysis.
Clinical pharmacology and therapeutics 1994;55(4):441-50.
1993: Z Hussein; G Richard Granneman; D Mukherjee; Emil Samara; Daniel L Hogan; M A Koss; Jon I Isenberg
Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.
British journal of clinical pharmacology 1993;36(5):391-8.
1993: Z Hussein; D J Mulford; B A Bopp; G Richard Granneman
Stereoselective pharmacokinetics of pazinaclone, a new non-benzodiazepine anxiolytic, and its active metabolite in healthy subjects.
British journal of clinical pharmacology 1993;36(4):357-61.
1993: Z Hussein; D J Mulford; B A Bopp; G Richard Granneman
Differences in the stereoselective pharmacokinetics of pazinaclone (DN-2327), a new anxiolytic, and its active metabolite after intravenous and oral single doses to dogs.
Drug metabolism and disposition: the biological fate of chemicals 1993;21(5):805-10.
1993: Z Hussein; K J Patterson; J E Lamm; John H Cavanaugh; G Richard Granneman
Effect of infusion duration on valproate pharmacokinetics.
Biopharmaceutics & drug disposition 1993;14(5):389-99.
1993: S Y Chu; G Richard Granneman; P J Pichotta; JP Decourt; J Girault; J B Fourtillan
Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics.
Journal of clinical pharmacology 1993;33(5):480-5.
1993: S K Gupta; G Richard Granneman; Milton Packer; R S Boger
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure.
Journal of cardiovascular pharmacology 1993;21(5):834-40.
1993: Z Hussein; S Y Chu; G Richard Granneman
Enantioselective determination of DN-2327, a novel non-benzodiazepine anxiolytic, and/or its active metabolite in human plasma and urine using high-performance liquid chromatography.
Journal of chromatography 1993;613(1):113-20.
1993: Z Hussein; S Y Chu; G Richard Granneman
High-performance liquid chromatographic method for determination of DN-2327, a novel non-benzodiazepine anxiolytic, and/or its active metabolite in human plasma and urine.
Journal of chromatography 1993;613(1):105-12.
1992: S K Gupta; G Richard Granneman; R S Boger; N K Hollenberg; R R Luther
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor). I: Single dose study.
Drug metabolism and disposition: the biological fate of chemicals 1992;20(6):821-5.
1992: G Richard Granneman; P Carpentier; P J Morrison; A G Pernet
Pharmacokinetics of temafloxacin in humans after multiple oral doses.
Antimicrobial agents and chemotherapy 1992;36(2):378-86.
1992: Gerhard Mahr; Fritz Sörgel; G Richard Granneman; Martina Kinzig; P Muth; K Patterson; Uwe Fuhr; P Nickel; U Stephan
Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine.
Clinical pharmacokinetics 1992;22 Suppl 1():90-7.
1992: G Richard Granneman; U Stephan; B Birner; Fritz Sörgel; D Mukherjee
Effect of antacid medication on the pharmacokinetics of temafloxacin.
Clinical pharmacokinetics 1992;22 Suppl 1():83-9.
1992: Fritz Sörgel; G Richard Granneman; U Stephan; C Locke
Effect of cimetidine on the pharmacokinetics of temafloxacin.
Clinical pharmacokinetics 1992;22 Suppl 1():75-82.
1992: Fritz Sörgel; Gerhard Mahr; G Richard Granneman; U Stephan; P Nickel; P Muth
Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.
Clinical pharmacokinetics 1992;22 Suppl 1():65-74.
1992: G Richard Granneman; D Mukherjee
The effect of food on the bioavailability of temafloxacin. A review of 3 studies.
Clinical pharmacokinetics 1992;22 Suppl 1():48-56.
1992: Fritz Sörgel; G Richard Granneman; Gerhard Mahr; P Kujath; W Fabian; P Nickel
Hepatobiliary elimination of temafloxacin.
Clinical pharmacokinetics 1992;22 Suppl 1():33-42.
1992: G Richard Granneman; Gerhard Mahr; C Locke; P Nickel; W Kirch; W Fabian; Martina Kinzig; K G Naber; Fritz Sörgel
Pharmacokinetics of temafloxacin in patients with liver impairment.
Clinical pharmacokinetics 1992;22 Suppl 1():24-32.
1992: G Richard Granneman
Pharmacokinetics of temafloxacin after multiple oral administration.
Clinical pharmacokinetics 1992;22 Suppl 1():14-23.
1991: G Richard Granneman; D R Guay
The influence of age on the pharmacokinetics of temafloxacin.
The American journal of medicine 1991;91(6A):71S-75S.
1991: G Richard Granneman; R Braeckman; J Kraut; S Shupien; J C Craft
Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.
Antimicrobial agents and chemotherapy 1991;35(11):2345-51.
1991: G Richard Granneman; L L Varga
High-performance liquid chromatographic procedures for the determination of temafloxacin in biological matrices.
Journal of chromatography 1991;568(1):197-206.
1991: G Richard Granneman; P Carpentier; P J Morrison; A G Pernet
Pharmacokinetics of temafloxacin in humans after single oral doses.
Antimicrobial agents and chemotherapy 1991;35(3):436-41.
1987: G Richard Granneman; L T Sennello
High-performance liquid chromatographic procedures for the determination of difloxacin and its metabolites in biological matrices.
Journal of chromatography 1987;413():199-206.
1986: J M Machinist; B A Bopp; D J Anderson; G Richard Granneman; R C Sonders; K Tolman; K Buchi; D Rollins
Metabolism of 14C-estazolam in dogs and humans.
Xenobiotica; the fate of foreign compounds in biological systems 1986;16(1):11-20.
1984: G Richard Granneman; S I Wang; J W Kesterson; J M Machinist
The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism.
Hepatology (Baltimore, Md.) 1984;4(6):1153-8.
1984: J W Kesterson; G Richard Granneman; J M Machinist
The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies.
Hepatology (Baltimore, Md.) 1984;4(6):1143-52.
1984: T P Gibson; G Richard Granneman; J E Kallal; L T Sennello
Kinetics of cefsulodin in patients with renal impairment.
Reviews of infectious diseases 1984;6 Suppl 3():S689-97.
1984: G Richard Granneman; S I Wang; J M Machinist; J W Kesterson
Aspects of the metabolism of valproic acid.
Xenobiotica; the fate of foreign compounds in biological systems 1984;14(5):375-87.
1982: G Richard Granneman; L T Sennello
Precise high-performance liquid chromatographic procedure for the determination of cefsulodin, a new antipseudomonal cephalosporin antibiotic, in plasma.
Journal of pharmaceutical sciences 1982;71(10):1112-5.
1982: T P Gibson; G Richard Granneman; J E Kallal; L T Sennello
Cefsulodin kinetics in renal impairment.
Clinical pharmacology and therapeutics 1982;31(5):602-8.
1982: G Richard Granneman; L T Sennello
A very precise high-performance liquid chromatographic procedure for the determination of cefmenoxime, a new cephalosporin antibiotic, in plasma.
Journal of chromatography 1982;229(1):149-57.
1982: G Richard Granneman; L T Sennello; R C Sonders; B Wynne; E W Thomas
Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection.
Clinical pharmacology and therapeutics 1982;31(1):95-103.
1982: G Richard Granneman; L T Sennello; F J Steinberg; R C Sonders
Intramuscular and intravenous pharmacokinetics of cefmenoxime, a new broad-spectrum cephalosporin, in healthy subjects.
Antimicrobial agents and chemotherapy 1982;21(1):141-5.